|
Active substance |
tafamidis |
|
Holder |
Pfizer NV/SA |
|
Status |
closed |
|
Indication |
treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) |
|
Public documents |
|
|
Last update |
18/05/2021 |
Vyndaqel®
Last updated on 10/09/2024